oveporexton

News

Man yawning, covering his mouth with his hand

FDA kicks off review of Takeda's narcolepsy hopeful

The FDA has started a priority review of Takeda's oveporexton for sleep disorder narcolepsy, setting up a decision in the third quarter of the year.

News

Alkermes breaks new ground in narcolepsy with orexin drug

Alkermes' alixorexton is the first orexin 2 receptor agonist to show efficacy in phase 2 trials involving patients with both main narcolepsy subtypes.

News

Takeda's narcolepsy programme gets back on track

Takeda will move quickly ahead with regulatory filings for oveporexton as a treatment for narcolepsy after a pair of phase 3 wins.

FDA kicks off review of Takeda's narcolepsy hopeful

Alkermes breaks new ground in narcolepsy with orexin drug

Takeda's narcolepsy programme gets back on track

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks